TriSalus Life Sciences Statistics
Share Statistics
TriSalus Life Sciences has 32.34M
shares outstanding. The number of shares has increased by 12.27%
in one year.
| Shares Outstanding | 32.34M |
| Shares Change (YoY) | 12.27% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 8.77% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 171 |
| FTD / Avg. Volume | 0.35% |
Short Selling Information
The latest short interest is 35.55K, so 0.11% of the outstanding
shares have been sold short.
| Short Interest | 35.55K |
| Short % of Shares Out | 0.11% |
| Short % of Float | 0.18% |
| Short Ratio (days to cover) | 1.25 |
Valuation Ratios
The PE ratio is -4 and the forward
PE ratio is -15.15.
TriSalus Life Sciences's PEG ratio is
0.09.
| PE Ratio | -4 |
| Forward PE | -15.15 |
| PS Ratio | 4.51 |
| Forward PS | 1 |
| PB Ratio | -5.13 |
| P/FCF Ratio | -3.22 |
| PEG Ratio | 0.09 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for TriSalus Life Sciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.02,
with a Debt / Equity ratio of -0.91.
| Current Ratio | 2.02 |
| Quick Ratio | 1.63 |
| Debt / Equity | -0.91 |
| Debt / EBITDA | -0.65 |
| Debt / FCF | -0.57 |
| Interest Coverage | -11.7 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $267,554.55 |
| Profits Per Employee | $-302,118.18 |
| Employee Count | 110 |
| Asset Turnover | 1.23 |
| Inventory Turnover | 1.01 |
Taxes
| Income Tax | 6K |
| Effective Tax Rate | -0.02% |
Stock Price Statistics
The stock price has increased by -48.67% in the
last 52 weeks. The beta is 0.5, so TriSalus Life Sciences's
price volatility has been higher than the market average.
| Beta | 0.5 |
| 52-Week Price Change | -48.67% |
| 50-Day Moving Average | 5.41 |
| 200-Day Moving Average | 4.96 |
| Relative Strength Index (RSI) | 38.24 |
| Average Volume (20 Days) | 49,024 |
Income Statement
In the last 12 months, TriSalus Life Sciences had revenue of 29.43M
and earned -33.23M
in profits. Earnings per share was -1.25.
| Revenue | 29.43M |
| Gross Profit | 25.33M |
| Operating Income | -36.16M |
| Net Income | -33.23M |
| EBITDA | -36.16M |
| EBIT | -33.13M |
| Earnings Per Share (EPS) | -1.25 |
Full Income StatementBalance Sheet
The company has 8.53M in cash and 23.63M in
debt, giving a net cash position of -15.1M.
| Cash & Cash Equivalents | 8.53M |
| Total Debt | 23.63M |
| Net Cash | -15.1M |
| Retained Earnings | -279.55M |
| Total Assets | 23.97M |
| Working Capital | 10.44M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -40.84M
and capital expenditures 0, giving a free cash flow of -41.19M.
| Operating Cash Flow | -40.84M |
| Capital Expenditures | n/a |
| Free Cash Flow | -41.19M |
| FCF Per Share | -1.55 |
Full Cash Flow StatementMargins
Gross margin is 86.06%, with operating and profit margins of -122.88% and -112.92%.
| Gross Margin | 86.06% |
| Operating Margin | -122.88% |
| Pretax Margin | -102.07% |
| Profit Margin | -112.92% |
| EBITDA Margin | -122.88% |
| EBIT Margin | -122.88% |
| FCF Margin | -139.95% |
